Reserpine or chronic paroxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain

Neuropharmacology

Volumn 39, Issue 6, 2000, Pages 1075-1082

  Vilpoux, C ^a   Leroux Nicollet, I ^a   Naudon, L ^a   Raisman Vozari, R ^b   Costentin, J ^a  

^a U de Neuropsychopharmacologie Exp   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Antidepressant; Paroxetine; Reserpine; SSRIs; Vesicular monoamine transporter 2; VMAT2 mRNA

Indexed keywords

BRAIN MONOAMINE; CARRIER PROTEIN; MESSENGER RNA; PAROXETINE; RESERPINE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG BINDING; IMMUNOREACTIVITY; MALE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEROTONINERGIC SYSTEM;

ANIMALS; AUTORADIOGRAPHY; BINDING SITES; BIOLOGICAL TRANSPORT; BRAIN; CITALOPRAM; DOPAMINE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NEUROPEPTIDES; NOREPINEPHRINE; PAROXETINE; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; RESERPINE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TETRABENAZINE; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0034102512     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00210-5     Document Type: Article

References (40)

1. Bel N., Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse. 15(3):1993;243-245.
2. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends in Pharmacological Sciences. 15:1994;220-226.
3. Blier P., de Montigny C., Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatment: preclinical evidence. Journal of Clinical Psychiatry. 51(4):1990;14-20.
4. Bolden-Watson C., Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sciences. 52:1993;1023-1029.
5. 3H]-mazindol binding to the dopamine transporter in the nucleus accumbens are delayed after chronic treatments by GBR 12783 or cocaine. The Journal of Pharmacology and Experimental Therapeutics. 278(1):1996;330-337.
6. Caley C.F., Weber S.S. Paroxetine: a selective serotonin reuptake inhibiting antidepressant. Annals of Pharmacotherapy. 27:1993;1212-1222.
7. Chesselet M.-F., Weiss L., Wuenschell C., Tobin A.J., Affolter H.U. Comparative distribution of mRNA for glutamic acid decarboxylase, tyrosine hydroxylase, and tachykinins in the basal ganglia: an in situ hybridization study in the rodent brain. Journal of Comparative Neurology. 262:1987;125-140.
8. 3H]imipramine. The Journal of Pharmacology and Experimental Therapeutics. 242(1):1987;364-371.
9. 125I] iodoketanserin. Neuroscience. 33:1989;341-349.
10. 3H]-paroxetine binding and serotonin content of rat brain: absence of changes following antidepressant treatments. European Journal of Pharmacology. 235:1993;137-142.
11. Frize E.D. Mental depression in hypertensive patients treated for long periods with high doses of reserpine. New England Journal of Medicine. 251:1954;1006-1008.
12. 4 receptors in rats. Naunyn Schmiedebergs Archives of Pharmacology. 356(1):1997;22-28.
13. 3H] paroxetine binding to cerebral cortical membranes of the rat. Neuropharmacology. 26(8):1987;1087-1092.
14. Henry J.-P., Scherman D. Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochemical Pharmacology. 38(15):1989;2395-2404.
15. Hollister L.E. New psychotherapeutic drugs. Journal of Clinical Psychopharmacology. 14(1):1994;50-63.
16. 2 receptors in rat brain: an autoradiographic study. Synapse. 14:1993;324-331.
17. Kovachich G.B., Aronson C.E., Brunswick D.J. Effect of repeated administration of antidepressants on serotonin uptake sites in limbic and neocortical structures of rat brain determined by quantitative autoradiography. Neuropsychopharmacology. 7(4):1992;317-324.
18. 1A autorecepteurs in rats treated with fluoxetine or paroxetine. Naunyn Schmiedebergs Archives of Pharmacology. 352(2):1995;141-148.
19. 3H] dihydrotetrabenazine. Neuroscience Letters. 117:1990;1-7.
20. Lesch K.P., Aulakh C.S., Wolosin B.L., Tolliver T.J., Hill J.L., Murphy D.L. Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Molecular Brain Research. 17:1993;31-35.
21. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry. 193:1951;265-275.
22. Mahata S.K., Mahata M., Fischer-Colbrie R., Winkler H. Reserpine causes differential changes in the mRNA levels of chromogranin B, secretogranin II, carboxypeptidase H, alpha-amidating monooxygenase, the vesicular amine transporter and of synapsin/synaptophysin in rat brain. Molecular Brain Research. 19:1993;83-92.
23. 14C-plastic standards for quantitative autoradiography using LKB Ultrofilm or Amersham Hyperfilm. Neuroscience Letters. 121:1991;211-214.
24. Montgomery S.A. Selective serotonin reuptake inhibitors in the acute treatment of depression. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;1043-1050 Raven Press, New York. Chapt. 89.
25. Naudon L., Leroux-Nicollet I., Costentin J. Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra. Neuroscience Letters. 173:1994;1-4.
26. Naudon L., Leroux-Nicollet I., Raisman-Vozari R., Botton D., Costentin J. Time-course of modifications elicited by reserpine on the density and mRNA synthesis of the vesicular monoamine transporter and on the density of the membrane dopamine uptake complex. Synapse. 21:1995;29-36.
27. Naudon L., Raisman-Vozari R., Edwards R.H., Leroux-Nicollet I., Peter D., Liu Y., Costentin J. Reserpine affects differentially the density of the vesicular monoamine transporter and dihydrotetrabenazine binding sites. European Journal of Neuroscience. 8:1996;842-846.
28. Nieuwenhuys R. Monoamines. Chemoarchitecture of the Brain. 1985;11-44 Springer-Verlag, Berlin/Heidelberg/New York/Tokyo.
29. Pellegrino L.J., Pellegrino A.S., Cushman A.J. A Stereotaxic Atlas of the Rat Brain. 1979;Plenum Press, New York.
30. Peter D., Jimenez J., Liu Y., Kim J., Edwards R.H. The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. Journal of Biological Chemistry. 269:1994;7231-7237.
31. Peter D., Liu Y., Sternini C., de Giorgio R., Brecha N., Edwards R.H. Differential expression of two vesicular monoamine transporters. Journal of Neuroscience. 15:1995;6179-6188.
32. Piñeyro G., Blier P., Dennis T., de Montigny C. Desensitization of the neuronal 5-HT carrier following its long-term blockade. Journal of Neuroscience. 14(5):1994;3036-3047.
33. Raisman-Vozari R., Hirsch E., Javoy-Agid F., Vassort C., Savasta M., Feuerstein C., Thibault J., Agid Y. Quantitative autoradiography of tyrosine hydroxylase immunoreactivity in the rat brain. Journal of Neurochemistry. 57(4):1991;1212-1222.
34. Segal D.S., Sullivan J.L., Kuckzenski R.T., Mandell A.J. Effects of long-term reserpine treatment on brain tyrosine hydroxylase and behavioral activity. Science. 173:1971;847-849.
35. Schuldiner S. A molecular glimpse of vesicular monoamine transporter. Journal of Neurochemistry. 62:1994;2067-2078.
36. 125I]RTI-55. Synapse. 16:1994;263-268.
37. Spurlock G., Buckland P., O'Donovan M., McGuffin P. Lack of effect of antidepressant drugs on the levels of mRNAs encoding serotonergic receptors, synthetic enzymes and 5-HT transporter. Neuropharmacology. 33(3/4):1994;433-440.
38. Staley J.K., Talbot J.Z., Ciliax B.J., Miller G.W., Levey A.I., Kung M.-P., Kung H.F., Mash D.C. Radioligand binding and immunoautoradiographic evidence for a lack of toxicity to dopaminergic nerve terminals in human cocaine overdose victims. Brain Research. 747:1997;219-229.
39. Vander Borght T., Kilbourn M., Desmond T., Kuhl D., Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. European Journal of Pharmacology. 294:1995;577-583.
40. Wilson M., Kish S.J. The vesicular monoamine transporter in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. Journal of Neuroscience. 16(10):1996;3507-3510.